Loading…
← CockpitCompetitor Analysis › 000403.SZ Pacific Shuanglin Bio-pharmacy Co., Ltd. Class AOpen in the cockpit ↗

Pacific Shuanglin Bio-pharmacy Co., Ltd. Class A000403.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese company classified under health care/biotechnology; specific business segments not established from available knowledge.

Momentum neutral 50
Mkt cap
$1.24B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$8.98M
20-day average traded
Fwd P/E
26.5×
forward earnings
ROIC−WACC
-1.6 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
156 days
23 Apr 2027
Close · CNYCN¥8.89
1D-1.1%
1W-5.2%
1M-8.5%
3M-20.4%
6M-20.6%
YTD-35.1%
1Y-43.4%
ATR %2.8%
52w lowhigh45.9% off high

What Pacific Shuanglin Bio-pharmacy does

Chinese company classified under health care/biotechnology; specific business segments not established from available knowledge.

Where it sits in the supply chain

  • Health Care
  • Biotechnology

Moat: none

Headquarters: China · Employees: 2,755

Pacific Shuanglin Bio-pharmacy at a glance

Size Pacific Shuanglin Bio-pharmacy (000403.SZ) is a China Health Care company (Biotechnology) with a market value of $1.24B, the 1799th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.89 on 18 Nov 2026.

Performance Over six months the shares fell 20.6%, against -20.3% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 19 in its peer set.

Growth Revenue grew 1.5% over the last twelve months (peer median +15.3%); the operating margin is 9.7% (peer median -295.1%).

Valuation It trades at 26.5× forward earnings against a peer median of 41.3× (3rd cheapest of 7).

Capital Return on invested capital runs 1.6 points below its cost of capital (5.0% WACC).

Next results Next results expected around 23 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026000403.SZ 83Peer median 79
Six months, rebased to 100: Pacific Shuanglin Bio-pharmacy against the median of its 20 peers (local-currency closes).

Pacific Shuanglin Bio-pharmacy financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.42BCN¥2.62BCN¥2.64BCN¥2.32BCN¥2.39B
Revenue growth—-1%+14%-3%—
Gross profitCN¥895MCN¥1.04BCN¥1.26BCN¥1.15BCN¥1.20B
EBITDAn/aCN¥715MCN¥929MCN¥781MCN¥716M
Net incomeCN¥212MCN¥419MCN¥745MCN¥612MCN¥587M
Free cash flow-CN¥164M-CN¥478M-CN¥109MCN¥379MCN¥190M
Capital expenditureCN¥226MCN¥333MCN¥521MCN¥377MCN¥379M
Total debtCN¥1.06BCN¥829MCN¥672MCN¥503MCN¥407M

Quarterly statements and history in the cockpit →

Pacific Shuanglin Bio-pharmacy competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%301207688739MLYSAKUMSTSHANVAXNUVBCMPSTYRA4588ANABVORABSI000403.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Pacific Shuanglin Bio-pharmacy is the large dot.

Fundamentals: revenue growth against valuation

-50%-25%0%+25%0×50×100×301207688739AKUMSNVAX6185ANAB000403.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pacific Shuanglin Bio-pharmacy is the large dot.

Pacific Shuanglin Bio-pharmacy competitors and peer comparison

How Pacific Shuanglin Bio-pharmacy compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pacific Shuanglin Bio-pharmacy against its 20 peers (data as of 18 Nov 2026)
Measure000403.SZPeer medianRank in peer set
1-month return-8.5%-13.4%8th highest of 21
6-month return-20.6%-20.3%9th lowest of 19
Distance from 52-week high-45.9%-49.0%9th highest of 21
Revenue growth (TTM)+1.5%+15.3%7th lowest of 15
Operating margin9.7%-295.1%3rd highest of 16
Forward P/E26.5×41.3×3rd cheapest of 7
ROIC minus cost of capital-1.6 pp-8.7 pp3rd highest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%26.5×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%38.6×33.2%-13.1%
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%44.0×6.6%-7.0%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%25.6×15.3%+9.9%
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%n/an/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%134.6×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%n/an/an/a
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%n/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%n/an/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%60.5×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%n/an/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%n/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%n/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%4.9×0.5%+25.6%
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%n/an/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%n/an/an/a

Questions

Which companies are Pacific Shuanglin Bio-pharmacy's closest peers?
The cockpit's peer set: Hualan Biological Vaccine (301207.SZ), Liaoning Chengda Biotechnology (688739.SS), Mineralys Therapeutics (MLYS), Akums Drugs and Pharmaceuticals (AKUMS.NS), Taysha Gene Therapies (TSHA), Novavax (NVAX), Zhuhai Trinomab Pharmaceutical (688806.SS), Kardigan (KARD).
Is Pacific Shuanglin Bio-pharmacy expensive compared with its peers?
On forward p/e it trades at 26.5× against a peer median of 41.3×, 3rd cheapest of 7 in its peer set.
How has Pacific Shuanglin Bio-pharmacy stock performed?
Over six months to 18 Nov 2026 the shares returned -20.6% against -20.3% for the median peer; over one year -43.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.